Enzyme Replacement Therapy with Idursulfase in Patients with Mucopolysaccharidosis Type II: Literature Review
Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is X-linked hereditary disease from the group of lysosomal storage disease. Its prevalence is 3–7 cases per 1 million live-born boys. MPS II occurs due to the deficiency of iduronate-2-sulfatase enzyme because of pathological changes in the str...
Saved in:
| Main Authors: | Nato D. Vashakmadze, Natalya V. Zhurkova, Olga B. Gordeeva, Elena V. Komarova, Tatyana E. Privalova, Anastasya I. Rykunova, Marina А. Babaykina |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2021-12-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/2791 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Idursulfase Beta (Hunterase) Therapeutic Experience in a Patient with Mucopolysaccharidosis Type II
by: Nato D. Vashakmadze, et al.
Published: (2023-08-01) -
Clinical Case of Drug Allergy to Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II
by: Julia G. Levina, et al.
Published: (2022-07-01) -
Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II
by: Julia G. Levina, et al.
Published: (2021-12-01) -
Mucopolysaccharidosis type II: Enzyme Replacement Therapy Efficiency
by: Nato D. Vashakmadze, et al.
Published: (2020-02-01) -
Experience of Idursulfase Beta Administration in the Child with Mucopolysaccharidosis Type II: Clinical Case
by: Tatiana K. Kruchina, et al.
Published: (2020-12-01)